Snowball logo
logo
BNGO_logo

Bionano Genomics, Inc

BNGO โ€ข NASDAQ
$1.18-$0.01ย  (0.84%)
Estimate
EPS
-4.5
Beta
1.617
Growth
Revenue, YoY
21.36%
Net income, YoY
-8.25%
FCF, YoY
-33.93%
Forecast
EPS (FWD)
-1.11
About the company
Ticker
BNGO
ISIN
US09075F1075
Country
United States of America
Sector (GICS)
Healthcare
Bionano Genomics, Inc., together with its subsidiaries, provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, China, Japan, South Korea, Singapore, India, and Australia. The company offers genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It also provides Saphyr and Stratys systems, which are sample-to-result solutions for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr and Stratys instruments, which are single-molecule imagers; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA; and Ionic purification system, which isolates and purifies nucleic acid molecules. In addition, the company offers Saphyr, Stratys, and Bionano compute servers; and VIA software, which offers one solution for solutions for cytogenetics and molecular genetics. Further, it provides testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.

Frequently asked questions

What sector does Bionano Genomics, Inc (BNGO) operate in?

Bionano Genomics, Inc belongs to the Healthcare sector and operates in the Medical Instruments & Supplies industry.

What is Bionano Genomics, Inc (BNGO) current stock price?

As of the latest data, Bionano Genomics, Inc stock price is $1.18, with a previous close of $1.19. Bionano Genomics, Inc lost -$0.01 in the last trading session, representing a -0.84% loss.

What is Bionano Genomics, Inc (BNGO) current market capitalization?

Bionano Genomics, Inc market cap is approximately 13.54 million.

What is Bionano Genomics, Inc (BNGO) Earnings Per Share (EPS)?

The trailing EPS is -$4.50, and the forward EPS is -$1.11.

What is Bionano Genomics, Inc (BNGO) EBITDA?

Bionano Genomics, Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -7.22 million.

Does Bionano Genomics, Inc (BNGO) pay dividends?

No. Bionano Genomics, Inc does not pay a dividend.

How did Bionano Genomics, Inc (BNGO) perform in its most recent earnings report?

In the last report (June 30, 2026), Bionano Genomics, Inc posted an EPS surprise of 8.57% and a revenue surprise of 9.3%.

What is Bionano Genomics, Inc (BNGO) beta (volatility) score?

Bionano Genomics, Inc has a beta of 1.617, suggesting it is more volatile than the market.